ABSTRACT
The insulinotropic and glucagon-releasing activity of acid extracts of rat hypothalami were tested in two bioassay systems using short-time incubation of isolated rat pancreatic islets and a rat insulinoma (RIN) cell line. Release of insulin and glucagon into the incubation medium was measured by radioimmunoassay. The major insulin-releasing and glucagon-releasing activity eluted in a broad zone in Sephacryl S-200 gel filtration in 30% acetic acid corresponding to the molecular weights between approximately 10 and 40 kD. The highest activity was eluted in a zone corresponding to 14 kD and was purified to homogeneity by means of two steps of reversed-phase HPLC. Amino acid analysis and SDS polyacrylamide gel electrophoresis indicated that the biologically active material was the rat small (myelin) basic protein characterized previously by Dunkley & Carnegie (1974). The purified rat hypothalamic material showed insulinotropic and glucagon-releasing activity indistinguishable from that of purified porcine myelin basic protein, and lost its insulinotropic activity when incubated with anti-myelin basic protein immunosorbent. We conclude that the major insulin-releasing and glucagon-releasing activity in acid extracts of the high-molecular-weight fractions of rat hypothalami is myelin basic protein.
Subject(s)
Glucagon/metabolism , Hypothalamus/analysis , Insulin/metabolism , Islets of Langerhans/metabolism , Myelin Basic Protein/administration & dosage , Tissue Extracts/administration & dosage , Amino Acids/analysis , Animals , Biological Assay , Cell Line, Transformed , Insulin Secretion , Insulinoma/metabolism , Molecular Weight , Myelin Basic Protein/isolation & purification , Neutralization Tests , Pancreatic Neoplasms/metabolism , Radioimmunoassay , Rats , Tissue Extracts/analysisABSTRACT
Antisera were raised against synthetic replicates of the carboxyl-terminal (C-terminal) fragment of the precursor to human GH-releasing factor (GRF) (pre-proGRF) whose structure was predicted from the complementary DNA cloned from a pancreatic tumor. These antisera were used along with antisera to human GRF itself to search for the presence of related molecules in the human hypothalamus, with an immunohistochemical approach. The antisera to pre-proGRF that recognize specifically the C-terminal amidated form of pre-proGRF stain GRF neurons in their cell bodies, fibers, and nerve endings that are in contact with portal capillaries of the median eminence. Antisera against the nonamidated form of the molecule did not give any staining in the hypothalamus. These results strongly suggest that human hypothalamic GRF derives from a precursor immunologically related (and probably identical) to the tumorous one and that this precursor is cleaved inside GRF cell bodies to give, in addition to the GRF-44-NH2 a second amidated peptide, the C-terminal pre-proGRF that is transported distally to nerve endings and most probably coreleased with GRF into portal capillaries.
Subject(s)
Growth Hormone-Releasing Hormone/analysis , Hypothalamus/analysis , Neurons/analysis , Peptide Fragments/analysis , Protein Precursors/analysis , Adult , Amides , Fluorescent Antibody Technique , Growth Hormone-Releasing Hormone/metabolism , Histocytochemistry , Humans , Hypothalamus/embryology , Immunoenzyme Techniques , Pancreatic Neoplasms/analysis , Protein Precursors/metabolismABSTRACT
UNLABELLED: This short review on GRF is divided into two parts: laboratory findings: Current status of the knowledge on the primary structure of all the GRFs isolated from mammalian sources; structure activity relationships as obtained with synthetic fragments and analogs of GRF; the mechanisms of action of GRF in vitro and in vivo; the localization by techniques of hypothalamic GRF neurons. CLINICAL STUDIES: A summary of past and current clinical studies with hGRF or fragments of hGRF establishing the dose range/effect in normal young adults; pharmacokinetics of hGRF; intravenous, sub-cutaneous and intranasal modes of administration; multi hours perfusions; the use of hGRF alone and in combination with other releasing factors as a diagnostic tool; early clinical results of stimulation of statural growth. Limited bibliography.
Subject(s)
Growth Hormone-Releasing Hormone/physiology , Hypothalamus/metabolism , Peptide Fragments/physiology , Animals , Growth Disorders/drug therapy , Growth Hormone-Releasing Hormone/metabolism , Growth Hormone-Releasing Hormone/therapeutic use , Humans , Kinetics , Peptide Fragments/metabolism , Peptide Fragments/therapeutic use , Species Specificity , Structure-Activity RelationshipSubject(s)
Growth Hormone-Releasing Hormone/physiology , Growth Hormone/metabolism , Peptide Fragments/physiology , Animals , Central Nervous System/physiology , Endocrine Glands/physiology , Growth/drug effects , Growth Hormone-Releasing Hormone/administration & dosage , Growth Hormone-Releasing Hormone/pharmacology , Growth Hormone-Releasing Hormone/toxicity , Haplorhini , Humans , Hypothalamus/physiology , Neural Pathways/physiology , Peptide Fragments/administration & dosage , Peptide Fragments/pharmacology , Peptide Fragments/toxicity , Pituitary Hormones/physiology , Somatostatin/physiology , Species SpecificityABSTRACT
The search for a peptide corresponding to the NH2-terminus of somatostatin-28 (SS-28) in tissues has led to the isolation and characterization of somatostatin-28[1-12] from pancreas and hypothalamus. Somatostatin-28[1-12]-like immunoreactivity [SS-28 [1-12]-LI] is widely distributed throughout the central nervous system and the digestive system of rodents and primates, reaching levels comparable to those of somatostatin-14 (SS-14). Antibodies directed against the C-terminal end of the dodecapeptide are more specific and constitute excellent markers for the "prosomatostatin" system in mammalian tissues. In rat brain, SS-28[1-12]-LI material is highly concentrated in nerve fibres and terminals, especially in the median eminence, layer I of neocortex, the outer molecular layer of the dentate gyrus and the striatum. Additionally, immunoreactivity is observed in large multipolar or occasionally pyramidal-like neurons of the neocortex. SS-28[1-12] is secreted from hypothalamus and amygdala by a calcium dependent mechanism. No biological role is presently known for the dodecapeptide. Two other peptides of Mr = 8000 (8 K) and Mr = 5000 (5 K) which contain SS-28[1-12] at their carboxy-termini are present in acid extracts from rat pancreas, brain and spinal cord. These two peptides were isolated from an acid extract of rat brains using ion-exchange chromatography, gel permeation chromatography and reverse-phase HPLC. Results from amino acid analysis and partial sequencing were compared to the sequence of the cDNA encoding rat pre-prosomatostatin (prepro-SS) and revealed that the 8 K peptide is a 76 amino acid molecule corresponding to prepro-SS[25-100] and that the 5K peptide, which contains 44 amino acids, corresponds to prepro-SS [57-100]. The 5 K peptide was generated after cleavage of a Leu-Leu bond at position 56-57 of prepro-SS. The four most predominant peptides of the "prosomatostatin system" presently characterized are: SS-14, SS-28[1-12], SS-28 and prepro-SS[25-100]. Studies on pooled perfusates from rat hypothalamic tissue show that prepro-SS[25-100] is released with SS-28[1-12] in vitro and accounts for 22% of the total SS-28[1-12]-like immunoreactive material released during depolarization. The 5 K peptide is apparently not secreted. The presence of prepro-SS[25-100] in brain implies that, first, prosomatostatin can serve as an immediate precursor for SS-14 without going through SS-28 as an intermediate step and second, other peptides could conceivably be derived from the cryptic portion of the precursor.
Subject(s)
Brain/metabolism , Peptide Fragments/metabolism , Somatostatin/metabolism , Amygdala/metabolism , Animals , Antibody Specificity , Hypothalamus/metabolism , Intestinal Mucosa/metabolism , Peptide Fragments/immunology , Peptide Fragments/isolation & purification , Protein Precursors/immunology , Protein Precursors/metabolism , Radioimmunoassay , Rats , Somatostatin/immunology , Somatostatin/isolation & purification , Somatostatin-28Subject(s)
Growth Hormone-Releasing Hormone/physiology , Hypothalamus/physiology , Neoplasms/physiopathology , Adenoma, Islet Cell/physiopathology , Animals , Growth Hormone/metabolism , Hormones/pharmacology , Humans , Pancreatic Neoplasms/physiopathology , Pituitary Gland/drug effects , Structure-Activity RelationshipABSTRACT
Peptides with high intrinsic growth hormone releasing activity (growth hormone-releasing factor, GRF) were isolated from 2100 ovine and 2600 caprine (goat) hypothalami by means of acid extraction, immunoaffinity chromatography, gel filtration and reverse phase HPLC. Structural characterization of the 44 amino acid ovine peptide by gas-liquid phase sequencing and peptide mapping established its primary structure as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser -Tyr-Arg-Lys-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met -Asn -Arg-Gln-Gln-GLy-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2. Caprine GRF was found to possess the same sequence except for the replacement of the isoleucine residue in position 13 with valine and thus is identical to bovine GRF.
Subject(s)
Goats/metabolism , Growth Hormone-Releasing Hormone/isolation & purification , Hypothalamus/analysis , Sheep/metabolism , Amino Acid Sequence , Animals , Chromatography, Gas , Growth Hormone-Releasing Hormone/chemical synthesis , Species SpecificityABSTRACT
Growth hormone-releasing factor (GRF) was isolated from acid extracts of approximately 35,000 rat hypothalami by means of immunoaffinity chromatography, gel filtration and two steps of reverse-phase HPLC. Amino acid analysis, gas-liquid phases sequencing and peptide mapping established that rat GRF is a 43 amino acid peptide with the amino acid sequence His-Ala-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly- Gln-Leu-Tyr-Ala-Arg-Lys-Leu-Leu-His-Glu-Ile-Met-Asn-Arg-Gln-Gln-Gly- Glu-Arg-Asn-Gln-Glu-Gln-Arg-Ser-Arg-Phe-Asn-OH, confirming the primary structure reported earlier (Spiess et al Nature 303, 532 (1983).
Subject(s)
Growth Hormone-Releasing Hormone/isolation & purification , Hypothalamus/analysis , Amino Acid Sequence , Animals , Chromatography, Affinity , Chromatography, Gel , Chromatography, High Pressure Liquid , Male , RatsABSTRACT
A 41 amino acid peptide with high intrinsic corticotropin-releasing activity was isolated from 1000 bovine hypothalami by means of immunoaffinity chromatography, gel filtration, and two steps of reverse phase HPLC. The primary structure of the amino terminal 39 amino acids was characterized by gas phase sequence analysis. The sequence of the amidated carboxyl terminal dipeptide was established by digestion of the intact natural product with Staphylococcus aureus V8 protease, dansylation of the digest and comparative reverse phase liquid chromatography studies with the synthetic dansylated dipeptides Ile-Ala-NH2, Ile-Ala-OH, Ala-Ile-NH2 and Ala-Ile-OH. The complete structure of the bovine corticotropin-releasing factor was established as: Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val- Leu- Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Asn-Asn-Arg-Lys-Leu- Leu- Asp-Ile-Ala-NH2 using approximately 650 pmol of material.
Subject(s)
Corticotropin-Releasing Hormone/isolation & purification , Hypothalamus/analysis , Amino Acid Sequence , Animals , Cattle , Chromatography, Affinity , Chromatography, Gel , Chromatography, High Pressure Liquid , RadioimmunoassayABSTRACT
The hypophysiotropic peptide, growth hormone-releasing factor (GRF), was isolated from human hypothalamic-hypophysial tissues by means of acid extraction, immunoaffinity chromatography, gel filtration, and two steps of reverse-phase high-performance liquid chromatography. Amino acid sequence determination using a gas-phase sequencer and reverse-phase liquid chromatography of the native peptide and its synthetic replicates showed its primary structure to be as follows: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln -Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser -Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, which is identical to that of the GRF recently isolated and characterized from a human pancreatic tumor that had caused acromegaly. Human hypothalamic GRF shows major homologies (93%, 89%, and 86%, respectively) when its primary structure is compared to that of the hypothalamic GRF from the porcine, bovine, caprine, and ovine species.
Subject(s)
Growth Hormone-Releasing Hormone/isolation & purification , Hypothalamus/analysis , Peptide Fragments/isolation & purification , Amino Acid Sequence , Amino Acids/analysis , Chromatography, Affinity , Chromatography, Gel , Humans , Pituitary Gland/analysisSubject(s)
Growth Hormone-Releasing Hormone/physiology , Amino Acid Sequence , Animals , Growth Hormone/metabolism , Growth Hormone-Releasing Hormone/isolation & purification , Growth Hormone-Releasing Hormone/pharmacology , Humans , Hypothalamus/physiology , Pancreas/physiology , Pituitary Gland/drug effects , Pituitary Gland/metabolismSubject(s)
Growth Hormone-Releasing Hormone/physiology , Peptide Fragments/physiology , Adenylyl Cyclases/physiology , Amino Acid Sequence , Amino Acids/analysis , Animals , Brain/drug effects , Cells, Cultured , Chemical Phenomena , Chemistry , Chromatography , Chromatography, High Pressure Liquid , Cyclic AMP/physiology , Dinoprostone , Dose-Response Relationship, Drug , Growth Hormone/metabolism , Growth Hormone-Releasing Hormone/antagonists & inhibitors , Growth Hormone-Releasing Hormone/chemical synthesis , Growth Hormone-Releasing Hormone/isolation & purification , Growth Hormone-Releasing Hormone/pharmacology , Histocytochemistry , Humans , Hypothalamus/analysis , Pancreatic Neoplasms/analysis , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/chemical synthesis , Peptide Fragments/isolation & purification , Peptide Fragments/pharmacology , Pituitary Gland/drug effects , Pituitary Gland/metabolism , Prostaglandins E/pharmacology , Protein Precursors , Radioimmunoassay , Somatostatin/pharmacology , Structure-Activity Relationship , Tissue DistributionABSTRACT
A 44 amino acid peptide with high intrinsic growth hormone releasing activity was isolated from 500 bovine hypothalami by means of acid extraction, immunoaffinity chromatography, gel filtration, and two steps of reverse phase HPLC. The growth hormone releasing factor was structurally characterized by gas phase sequence analysis. Reverse phase liquid chromatography of the native peptide and synthetic replicates showed that the molecule possesses an amide rather than a free acid at its carboxyl terminus. The structure of the peptide was established as: Tyr Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala -Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln -Gly-Ala-Lys-Val-Arg-Leu-NH2 using approximately 2 nmol of material.
Subject(s)
Growth Hormone-Releasing Hormone/isolation & purification , Hypothalamus/analysis , Amino Acid Sequence , Amino Acids/analysis , Animals , Cattle , Chemical Phenomena , Chemistry , Chromatography, Gel , Chromatography, High Pressure Liquid , Immunochemistry , Peptides/isolation & purification , RadioimmunoassayABSTRACT
A 44 amino acid peptide with high intrinsic growth hormone releasing activity was isolated from 2500 porcine hypothalami by means of acid extraction, immunoaffinity chromatography, gel filtration, and 2 steps of reverse phase HPLC. The growth hormone releasing factor was structurally characterized by gas phase sequence analyses of the intact peptide and its carboxyl terminal cyanogen bromide digestion fragment. Reverse phase liquid chromatography of the native peptide and synthetic replicates showed that the molecule possesses an amide rather than a free acid at its carboxyl terminus. The structure of the peptide was established as: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Arg-Val-Arg-Leu-NH2 using approximately 6 nmol of material.
Subject(s)
Growth Hormone-Releasing Hormone/isolation & purification , Hypothalamus/analysis , Amino Acid Sequence , Animals , Chromatography, Liquid , Cyanogen Bromide , Humans , Swine , Trypsin/metabolismABSTRACT
Human hypothalamic growth hormone-releasing factor (GRF) was purified by gel filtration and reverse-phase HPLC. Bioassay and two radioimmunoassays of different specificity revealed the presence of two major forms of GRF-activity which coelute with human pancreas GRFs, hpGRF-44-NH2 and hpGRF-40 previously characterized in pancreas tumors. The bioactive material coeluting with hpGRF-44-NH2 is recognized by two antibodies which are directed against the amidated COOH-terminal sequence and the central portion of the GRF-44 peptide. The bioactive GRF which coelutes with hpGRF-40 reacts only with the antibody directed against the central portion of hpGRF. These data strongly suggest that the human hypothalamus contains the same major forms of GRF that were identified in pancreas tumors responsible for acromegaly in the absence of a pituitary tumor.
Subject(s)
Growth Hormone-Releasing Hormone/analysis , Hypothalamus/analysis , Biological Assay , Female , Growth Hormone-Releasing Hormone/pharmacology , Hormones, Ectopic/analysis , Humans , Male , Molecular Weight , Pancreatic Neoplasms/analysis , Protein Processing, Post-Translational , Radioimmunoassay , Structure-Activity RelationshipSubject(s)
Calcium/metabolism , Cobalt/pharmacology , Cyclic AMP/metabolism , Growth Hormone-Releasing Hormone/pharmacology , Growth Hormone/metabolism , Peptide Fragments/pharmacology , Pituitary Gland/physiology , Prostaglandins E/pharmacology , 1-Methyl-3-isobutylxanthine/pharmacology , 8-Bromo Cyclic Adenosine Monophosphate , Animals , Antihypertensive Agents/pharmacology , Cholera Toxin/pharmacology , Colforsin , Cyclic AMP/analogs & derivatives , Cyclic AMP/pharmacology , Dinoprostone , Diterpenes/pharmacology , Hypothalamus/physiology , Kinetics , Pituitary Gland/drug effects , Radioimmunoassay , Rats , Somatostatin/analogs & derivativesSubject(s)
Brain Chemistry , Protein Precursors/isolation & purification , Somatostatin/analogs & derivatives , Animals , Chromatography, Gel , Female , Hypothalamus/analysis , Molecular Weight , Peptide Fragments/analysis , Radioimmunoassay , Rats , Rats, Inbred Strains , Somatostatin/isolation & purificationABSTRACT
A highly specific radioimmunoassay for one of the putative adrenomedullary [Met]enkephalin precursors, BAM-12P (Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-OH), has been developed. The BAM-12P antibodies recognize the COOH-terminal fragment of the peptide from Arg7 to Glu12 and do not crossreact with [Met5]- or [Leu5]enkephalin or any of their COOH-terminal lysine or arginine extended analogs. Specificity for the COOH-terminal Glu-OH is suggested by the 100% crossreactivity with BAM-12P5-12 and 0.3% crossreactivity with BAM-12P5-12 amide. Using these antibodies, we have measured three forms of BAM-12P-like immunoreactivity in extracts of bovine adrenal medulla, of which the major form (greater than 90%) corresponds to BAM-12P by molecular weight. Extracts of bovine adrenal cortex contain 1% the amount of a BAM-12P-like material (Mr approximately 1400; 20 ng per gland), possibly due to crosscontamination with adrenomedullary tissue. The major form of BAM-12P-like material in extracts of bovine neurointermediate pituitaries is of higher molecular weight than authentic BAM-12P (Mr approximately 4000); the remaining material (10%) corresponds to BAM-12P by molecular weight. There is no detectable BAM-12P-like immunoreactivity in crude or purified extracts of bovine anterior pituitaries. Extracts of bovine hypothalamic tissues contain small amounts of BAM-12P immunoreactivity (approximately 2 ng per fragment) which can be detected as one molecular form corresponding to a 1400-dalton molecule. The results indicate that the enkephalin precursor found in the adrenal medulla also may be present in the pituitary and hypothalamus. Furthermore, the processing of this molecule appears to be tissue-specific.
Subject(s)
Adrenal Glands/metabolism , Endorphins/metabolism , Enkephalin, Methionine/analogs & derivatives , Enkephalins/metabolism , Hypothalamus/metabolism , Pituitary Gland/metabolism , Protein Precursors/metabolism , Adrenal Cortex/metabolism , Adrenal Medulla/metabolism , Animals , Cattle , Cross Reactions , RadioimmunoassayABSTRACT
Acid extracts from rat pancreas and hypothalamus were analyzed for the presence of the antigenic determinant corresponding to the NH2 terminus of somatostatin-28 (SS28), using an antiserum directed against amino acids 1 to less than or equal to 11 of the SS28 molecule. On gel permeation chromatography the majority of the immunoreactive material from each tissue extract eluted in one zone compatible with a peptide of 1250 daltons. Purification of this immunoreactive material by reverse-phase HPLC and cation-exchange chromatography yielded two immunoreactive peptides from each tissue extract. The amino acid compositions of both peptides in pancreas and hypothalamus correspond to the fragment 1-12 of SS28. The more hydrophobic peptide from each tissue coeluted with synthetic SS28-(1-12) on HPLC, while the other one coeluted with synthetic SS28-(1-12)-amide. We conclude that the prosomatostatin fragment Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-OH is present in both rat hypothalamus and rat pancreas.
Subject(s)
Hypothalamus/metabolism , Pancreas/metabolism , Somatostatin/metabolism , Amino Acid Sequence , Animals , Antibody Specificity , Peptide Fragments/metabolism , Rats , Somatostatin/immunology , Somatostatin-28ABSTRACT
A peptide with somatostatin-like immuno- and bioactivity has been isolated from an aqueous extract of 96 800 rat hypothalamic by means of immunoaffinity chromatography, gel filtration and reverse-phase high-performance liquid chromatography (HPLC). Chemical characterization by amino acid analysis, tryptic peptide mapping and retention behavior in two HPLC system showed that the peptide was indistinguishable from somatostatin-28 previously characterized from several species. This evidence suggests that rat hypothalamic somatostatin-28 is identical in structure to porcine and ovine somatostatin-28.